Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03007875
  4. Details
NCT03007875 Clinical Trial

High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03007875
Other study ID # HANK-nsclc
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date December 1, 2016
Est. completion date September 1, 2019

Study information
Verified date December 2018
Source Fuda Cancer Hospital, Guangzhou
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of non-small cell lung cancer.

Description:

By enrolling patients with small metastases of non-small cell lung cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of high-activity natural killer cells.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Recruitment information / eligibility
Status Completed
Enrollment 20
Est. completion date September 1, 2019
Est. primary completion date December 1, 2017
Accepts healthy volunteers No
Gender All
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria:

- All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence

- Body tumor 1-6, the maximum tumor length < 2 cm

- KPS = 70, lifespan > 6 months

- Platelet count = 80×109/L,white blood cell count = 3×109/L, neutrophil count = 2×109/L, hemoglobin = 80 g/L

Exclusion Criteria:

- Patients with cardiac pacemaker

- Patients with brain metastasis

- Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• high-activity natural killer
Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.

Locations
Country Name City State
China Fuda cancer institute of Fuda cancer hospital Guangzhou Guangdong

Sponsors (2)
Lead Sponsor Collaborator
Fuda Cancer Hospital, Guangzhou Shenzhen Hank Bioengineering Institute

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Relief degree of tumors It will be evaluated by the Response Evaluation Criteria in Solid Tumors(RECIST) 3 months
Secondary Progress free survival(PFS) 1 year
Secondary Overall survival(OS) 3 years
See also
  Status Clinical Trial Phase
Completed NCT01523340 - A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
Recruiting NCT03956641 - Evolution of the Physical Condition in Treated Cancer Patients N/A
Active, not recruiting NCT02035683 - PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy N/A
Completed NCT01848613 - Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC Phase 4
Suspended NCT01320501 - Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer Phase 4
Terminated NCT01471964 - Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT06127940 - K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation Phase 1
Terminated NCT04069936 - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC Phase 2
Terminated NCT03445000 - ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer Phase 2
Terminated NCT03386929 - Survival Prolongation by Rationale Innovative Genomics Phase 1/Phase 2
Recruiting NCT02922764 - A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer Phase 1
Terminated NCT01574300 - Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Active, not recruiting NCT04646824 - Almonertinib With Chemotherapy in mEGFR NSCLC Phase 2
Completed NCT01966003 - Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer Phase 3
Recruiting NCT03656094 - Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors Phase 2
Terminated NCT01348126 - Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Phase 2/Phase 3
Active, not recruiting NCT03469960 - Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr Phase 3
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT04793815 - Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) N/A
Terminated NCT01380795 - Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas Early Phase 1